Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Zhonghua Yang, Shunping Li, Xuewen Wang & Gang Chen. (2022) Health state utility values derived from EQ-5D in psoriatic patients: a systematic review and meta-analysis. Journal of Dermatological Treatment 33:2, pages 1029-1036.
Read now
Read now
Xiaoying Jia, Yang Zhao, Justin Carrico, Thor-Henrik Brodtkorb, Alan M. Mendelsohn, Simon Lowry, Steve Feldman, Jashin J. Wu & April W. Armstrong. (2022) Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment 33:2, pages 740-748.
Read now
Read now
Steven R. Feldman, Braulio Gomez, Xiangyi Meng & Rebecca Germino. (2021) Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials. Journal of Dermatological Treatment 32:7, pages 709-715.
Read now
Read now
Marco Galluzzo, Marina Talamonti, Valeria Manfreda, Dionisio Silvaggio, Chiara Tartaglia, Denis Roberto, Elena Campione & Luca Bianchi. (2021) Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies. Expert Opinion on Biological Therapy 21:2, pages 191-200.
Read now
Read now
Louis S. Matza, John E. Brazier, Katie D. Stewart, Lionel Pinto, Randall H. Bender, Leon Kircik, Jessica Jordan, Katherine J. Kim, Alex Mutebi, Hema N. Viswanathan & Alan Menter. (2019) Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI). Journal of Medical Economics 22:9, pages 936-944.
Read now
Read now
Jillian Frieder, Dario Kivelevitch, Connie Tran Fiore, Saadeddine Saad & Alan Menter. (2018) The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis. Expert Review of Clinical Immunology 14:1, pages 1-19.
Read now
Read now
Articles from other publishers (6)
Paulina Maravilla-Herrera, María Merino, Santiago Alfonso Zamora, Jesús Balea Filgueiras, José Manuel Carrascosa Carrillo, Olga Delgado Sánchez, Francisco Dolz Sinisterra, Antonio García-Ruiz, Pedro Herranz Pinto, Antonio Manfredi, José Martínez Olmos, Paloma Morales de los Ríos Luna, Lluís Puig, Sandra Ros & Álvaro Hidalgo-Vega. (2023) The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Frontiers in Public Health 11.
Crossref
Crossref
Fanni Rencz, Clara Mukuria, Alex Bató, Adrienn Katalin Poór & Aureliano Paolo Finch. (2022) A qualitative investigation of the relevance of skin irritation and self-confidence bolt-ons and their conceptual overlap with the EQ-5D in patients with psoriasis. Quality of Life Research 31:10, pages 3049-3060.
Crossref
Crossref
Jonathan Barker, Hannah Baker, Ayeda Nadeem, Dong-Ha Gu & Giampiero Girolomoni. (2021) Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis. Clinical Drug Investigation 41:11, pages 1011-1020.
Crossref
Crossref
Adrienn Katalin Poór, Fanni Rencz, Valentin Brodszky, László Gulácsi, Zsuzsanna Beretzky, Bernadett Hidvégi, Péter Holló, Sarolta Kárpáti & Márta Péntek. (2017) Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Quality of Life Research 26:12, pages 3409-3419.
Crossref
Crossref
Robert Bissonnette, Marc Bourcier, Melinda Gooderham, Chih-ho Hong, Ian Landells, Charles Lynde, Kim Papp, Yves Poulin, Ronald Vender & Marni C. Wiseman. (2017) Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. Journal of Cutaneous Medicine and Surgery 21:2_suppl, pages 2S-40S.
Crossref
Crossref
Jillian Frieder, Dario Kivelevitch & Alan Menter. (2017) Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature. Therapeutic Delivery 8:9, pages 737-746.
Crossref
Crossref